These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
632 related articles for article (PubMed ID: 12228209)
21. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Witzig TE Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398 [TBL] [Abstract][Full Text] [Related]
22. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399 [TBL] [Abstract][Full Text] [Related]
23. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713 [TBL] [Abstract][Full Text] [Related]
24. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Hainsworth JD; Spigel DR; Markus TM; Shipley D; Thompson D; Rotman R; Dannaher C; Greco FA Clin Lymphoma Myeloma; 2009 Jun; 9(3):223-8. PubMed ID: 19525191 [TBL] [Abstract][Full Text] [Related]
27. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study. Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575 [TBL] [Abstract][Full Text] [Related]
28. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Tobinai K; Watanabe T; Ogura M; Morishima Y; Hotta T; Ishizawa K; Itoh K; Okamoto S; Taniwaki M; Tsukamoto N; Okumura H; Terauchi T; Nawano S; Matsusako M; Matsuno Y; Nakamura S; Mori S; Ohashi Y; Hayashi M; Endo K Cancer Sci; 2009 Jan; 100(1):158-64. PubMed ID: 19018755 [TBL] [Abstract][Full Text] [Related]
29. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Vitolo U; Perrotti A; Fina M; Derenzini E; Baccarani M Cancer; 2008 Feb; 112(4):856-62. PubMed ID: 18189293 [TBL] [Abstract][Full Text] [Related]
30. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Ansell SM; Schilder RJ; Pieslor PC; Gordon LI; Emmanouilides C; Vo K; Czuczman MS; Witzig TE; Theuer C; Molina A Clin Lymphoma; 2004 Dec; 5(3):202-4. PubMed ID: 15636698 [TBL] [Abstract][Full Text] [Related]
31. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Winter JN Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146 [TBL] [Abstract][Full Text] [Related]
32. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Grillo-López AJ Semin Oncol; 2005 Feb; 32(1 Suppl 1):S44-9. PubMed ID: 15786025 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study. Ibatici A; Pica GM; Nati S; Vitolo U; Botto B; Ciochetto C; Petrini M; Galimberti S; Ciabatti E; Orciuolo E; Zinzani PL; Cascavilla N; Guolo F; Fraternali Orcioni G; Carella AM Br J Haematol; 2014 Mar; 164(5):710-6. PubMed ID: 24344981 [TBL] [Abstract][Full Text] [Related]
37. Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. Molina A; Krishnan A; Fung H; Flinn IW; Inwards D; Winter JN; Nademanee A Curr Stem Cell Res Ther; 2007 Sep; 2(3):239-48. PubMed ID: 18220907 [TBL] [Abstract][Full Text] [Related]
38. Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Vose JM; Bierman PJ; Loberiza FR; Bociek RG; Matso D; Armitage JO Leuk Lymphoma; 2007 Apr; 48(4):683-90. PubMed ID: 17454625 [TBL] [Abstract][Full Text] [Related]
39. Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Vaklavas C; Meredith RF; Shen S; Knox SJ; Micallef IN; Shah JJ; LoBuglio AF; Forero-Torres A Cancer Biother Radiopharm; 2013 Jun; 28(5):370-9. PubMed ID: 23530878 [TBL] [Abstract][Full Text] [Related]
40. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Gordon LI Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]